ArticleComputational and structural biotechnology journal2026
EMoMiS: A pipeline for epitope-based molecular mimicry search in protein structures with potential applications to SARS-CoV-2.
Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Structural homology and binding ability comparisons of epitope pair candidates for molecular mimicry triggering of type 1 diabetes mellitus.Oxford open immunology · 2026Article
- Applying the digital data and the bioinformatics tools in SARS-CoV-2 research.Computational and structural biotechnology journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The Epitope-based Molecular Mimicry Search (EMoMiS) pipeline developed in this study provides a valuable computational tool for predicting molecular mimicry between antigens. The novelty of the tool includes a prediction of antibody cross-reactivity, which can have beneficial or detrimental effects on the immune system. The developed pipeline can be seen as a tool for pandemic preparedness. First, EMoMiS can predict if antibodies produced by exposure to prior viruses can cross-react with a newly emerged pathogen, resulting in cross-protection. On the other hand, EMoMiS can suggest if molecular mimicry between a pathogen and human proteins can lead to autoimmune disorders, such that early preventive therapeutics strategies can be developed. After we first verified that EMoMiS could predict previously documented cross-reactivity between antibodies for the Zika virus with Dengue, the pipeline predicted examples of molecular mimicry between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike and other proteins, including thrombopoietin (TPO), a hormone that regulates systemic platelet concentrations. The study provides experimental support for the predicted molecular mimicry by showing increased TPO co-localization with platelets, complement-fixing IgM antibodies, and C3d in lung tissue sections from SARS-CoV-2 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.